您的位置:首页 > 论文页面
新型冠状病毒疫苗Meta分析
发表时间:2022-09-29 浏览量:1164 下载量:121
全部作者: | 杨明磊,鲍宇玲,谭松巍 |
作者单位: | 华中科技大学同济医学院药学院;华中科技大学同济医学院附属同济医院药学部 |
摘 要: | 目的:评价新型冠状病毒疫苗的有效性及安全性。采用方法:计算机检索PubMed,Web of Sciense,The Cochrane Library,并辅以手工检索相关杂志和纳入研究的参考文献。对国内外公开发表的符合入选标准的新冠疫苗Ⅰ期、Ⅱ期或Ⅲ期临床试验数据的研究文献,共纳入12篇文献,利用Revman 5.4和Stata 16.0软件进行荟萃分析(Meta分析)。主要结论:有效性,辉瑞疫苗>Moderna疫苗>Gamaleya研究所疫苗>北京生物制品研究所疫苗>武汉生物制品研究所疫苗>康希诺疫苗>阿斯利康/牛津大学疫苗>强生公司疫苗>科兴疫苗;不良反应发生率,核酸疫苗>病毒载体疫苗>灭活疫苗。研究结果为新冠疫苗受众者的选择和决策提供了科学依据,对新冠疫苗相关知识的普及也具有参考价值。 |
关 键 词: | 生物药物学;疫苗;Meta分析;新型冠状病毒;有效性;安全性 |
Title: | Meta-analysis of COVID-19 vaccine |
Author: | YANG Minglei, BAO Yuling, TAN Songwei |
Organization: | School of Pharmacy, Tongji Medical College, Huazhong University of Science & Technology; Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology |
Abstract: | Objective: To evaluate the efficacy and safety of novel Coronavirus vaccine. Methods: Literatures were retrieved from PubMed, Web of Sciense and The Cochrane Library, supplemented by manual retrieval of relevant journals and references put in this study. Total 12 published literatures about phase I, II or III clinical trials data of COVID-19 vaccine meeting the inclusion criteria were collected. The meta-analysis was performed using Revman 5.4 and Stata 16.0 software. Results: Efficacy, Pfizer vaccine>Moderna vaccine>Gamaleya Institute vaccine>Beijing Institute of Biological Products vaccine>Wuhan Institute of Biological Products vaccine>Concino vaccine>AstraZeneca/Oxford vaccine>Johnson & Johnson vaccine>Sinovac vaccine. Incidence of adverse effect, nucleic acid vaccine>viral vector vaccine>inactivated vaccine. This work provides a systematic basis for the selection and decision-making of COVID-19 vaccine audiences, and has reference value for popularizing related knowledge about COVID-19 vaccine. |
Key words: | biopharmaceutics; vaccine; Meta-analysis; COVID-19; effectiveness; safety |
发表期数: | 2022年9月第3期 |
引用格式: | 杨明磊,鲍宇玲,谭松巍. 新型冠状病毒疫苗Meta分析[J]. 中国科技论文在线精品论文,2022,15(3):332-340. |

请您登录
暂无评论